Search Results 1541-1550 of 17839 for Substance+dependence

  1. Nonalcoholic Fatty Liver Disease Clinical Trials - Mayo Clinic Research

    The purpose of this study is to assess a new drug to decrease liver fat in subjects with Non-Alcoholic Steatohepatitis or Non-Alcoholic Fatty Liver Disease.

  2. Clinical trials - Oncology (Medical)

    Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...

  3. A Study of the Large-scale Organization of the Brain and Producing Measurable Change with Intervention - Mayo Clinic

    ... drug intervention. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...

  4. Publications - Dan A. Schupack, M.D. - Mayo Clinic

    Histologic response to steroids in eosinophilic esophagitis is dependent on delivery compound. Dis Esophagus. 2022 Dec 31; 36 (1) View PubMed; Schupack DA ...

  5. Rem-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS - Mayo Clinic

    By condition, treatment or drug name. Search tips. Rem-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS. Print details.

  6. Effects of Background Composition, Tilt, and Rotation on Accuracy of the Subjective Visual Vertical - Mayo Clinic

    By condition, treatment or drug name. Search tips. Effects of Background Composition, Tilt, and Rotation on Accuracy of the Subjective Visual Vertical. Print ...

  7. Clinical trials - Oncology (Medical)

    Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...

  8. Publications - Manuel J. Rodriguez, M.D. - Mayo Clinic

    ... dependent breast tumor regression. Oncotarget. 2025 May 20; 16:379-381. View PubMed; Makovicka JL, Moore ML, Pollock JR, Rodriguez MJ, Shaha JS, Haglin JM ...

  9. Pressure-enabled Retrograde Occlusive Therapy With Embolization For Control Of Thyroid Disease (PROTECT Registry)

    By condition, treatment or drug name ... Prevalence of abnormal suppression was dependent on three factors: patient age, goitre type and estimated thyroid weight.

  10. Clinical trials - Oncology (Medical)

    Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...